NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Engitix Therapeutics

Engitix Therapeutics

Private
LondonHealthcare & Life Scienceshttps://engitix.com/

Last Round

Series A

Extension

Jan 8, 2026

Total Funding Raised

$86M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Engitix Therapeutics is a biotechnology company that develops therapies for cancer and fibrosis by targeting the extracellular matrix (ECM).

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Application

Keywords

extracellular matrixECMdrug discoveryfibrosis therapyoncologytarget identificationbioinformaticsmulti-omicsdrug target validationprecision medicinebiotech platformin silico drug discoveryAI drug discoverytherapeutic pipelineR&D collaboration

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Engitix Therapeutics Comparables

Compare Engitix Therapeutics with similar companies based on industry and business-model similarity.

Engitix Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Apmonia Therapeutics
76%
Aspect Biosystems
66%
leadXpro AG
64%

Engitix Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionJan 8, 2026
Series AJan 19, 2022
SeedNov 27, 2018

Key People

Founding team and executive leadership

Giuseppe Mazza

Co-Founder And CEO

Founding Team

Christopher Stevenson

Chief Scientific Officer

Executive Team

Engitix Therapeutics Investors

Notable investors and investment history

Engitix Therapeutics investors
InvestorRounds
Netherton InvestmentsSeed, Series A, Series A Extension
UCL BusinessSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 8, 2026

    Raised $25M in Series A Extension funding.

  • Nov 27, 2018

    $7M round led by Netherton Investments

Engitix Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Engitix Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Engitix Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon
Employee Range62
Year Founded2016
Last FundingJan 8, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.